1. Home
  2. NAMS

as 05-30-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Founded: 2019 Country:
Netherlands
Netherlands
Employees: N/A City: NARRDEN
Market Cap: 2.2B IPO Year: N/A
Target Price: $42.83 AVG Volume (30 days): 660.2K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.85 EPS Growth: N/A
52 Week Low/High: $14.06 - $27.29 Next Earning Date: 05-08-2025
Revenue: $47,140,000 Revenue Growth: 586.97%
Revenue Growth (this year): -55.59% Revenue Growth (next year): -15.81%

NAMS Daily Stock ML Predictions

Share on Social Networks: